SRR1797300
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 67
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
- PANCREAS_BETA_CELLS+0.480
- TNFA_SIGNALING_VIA_NFKB+0.480
- ANGIOGENESIS+0.440
- COAGULATION+0.430
- COMPLEMENT+0.370
- IL6_JAK_STAT3_SIGNALING+0.360
- UV_RESPONSE_DN+0.360
- INFLAMMATORY_RESPONSE+0.350
- TGF_BETA_SIGNALING+0.350
Top 10 suppressed
- DNA_REPAIR-0.290
- E2F_TARGETS-0.290
- MYC_TARGETS_V2-0.170
- OXIDATIVE_PHOSPHORYLATION-0.170
- G2M_CHECKPOINT-0.140
- CHOLESTEROL_HOMEOSTASIS-0.090
- NOTCH_SIGNALING-0.070
- SPERMATOGENESIS-0.070
- GLYCOLYSIS-0.060
- WNT_BETA_CATENIN_SIGNALING-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1797276 | — | cohortMD2 | 0.982 |
| 2 | MNG639 | — | — | 0.914 |
| 3 | SRR1797303 | — | cohortMD2 | 0.905 |
| 4 | MNG918 | — | — | 0.884 |
| 5 | MDT-AP-2910 | Med | Medulloblastoma | 0.875 |
| 6 | TCGA-DK-A1AF-01A-11R-A13Y-07 | — | — | 0.874 |
| 7 | BS_WRHDP7WF | EPN | Posterior Fossa EPN | 0.870 |
| 8 | SRR10900576 | — | — | 0.870 |
| 9 | SRR26320076 | — | — | 0.868 |
| 10 | SRR8526727 | — | cohortMD2 | 0.863 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.480 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.480 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| COAGULATION | 0.430 | Binimetinib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.360 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.350 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.340 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.330 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.290 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.270 | Remibrutinib | — uncovered |
| HYPOXIA | 0.260 | Idelalisib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |